SPIRONOLACTONE ( DrugBank: Spironolactone )

---

8 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1
58	肥大型心筋症	2
67	多発性嚢胞腎	1
86	肺動脈性肺高血圧症	6
113	筋ジストロフィー	2
210	単心室症	2
218	アルポート症候群	1
225	先天性腎性尿崩症	1

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05092984 (ClinicalTrials.gov)	June 22, 2022	28/9/2021	Evaluation of Spironolactone Efficacy in Patient With Rheumatoid Arthritis (RA)	Evaluation of Spironolactone Efficacy in Patient With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Spironolactone;Drug: Placebo	University Hospital, Strasbourg, France	NULL	Recruiting	18 Years	N/A	All	154	Phase 3	France

58. 肥大型心筋症

---

臨床試験数 : 126 /  薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02948998 (ClinicalTrials.gov)	May 14, 2018	27/10/2016	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial	Hypertrophic Cardiomyopathy;Fibrosis	Drug: Spironolactone	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Ruijin Hospital;RenJi Hospital;Shanghai Jiao Tong University Affiliated Sixth People's Hospital	Unknown status	18 Years	75 Years	All	260	Phase 4	China
2	NCT00879060 (ClinicalTrials.gov)	November 2007	8/4/2009	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic	Myocardial Fibrosis;Hypertrophic Cardiomyopathy	Drug: spironolactone	Tufts Medical Center	NULL	Recruiting	18 Years	70 Years	Both	95	Phase 4	United States

67. 多発性嚢胞腎

---

臨床試験数 : 221 /  薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01853553 (ClinicalTrials.gov)	July 2013	8/5/2013	Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney	ADPKD	Drug: Spironolactone;Drug: Sugar pill	University of Colorado, Denver	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	20 Years	55 Years	All	61	Phase 3	United States

86. 肺動脈性肺高血圧症

---

臨床試験数 : 1,205 /  薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03344159 (ClinicalTrials.gov)	April 1, 2018	28/9/2017	Spironolactone Therapy in Chronic Stable Right HF Trial	Spironolactone Therapy in Chronic Stable Right HF Trial	Chronic Right-Sided Heart Failure;Pulmonary Arterial Hypertension;Pulmonary Hypertension, Primary, 2;Pulmonary Hypertension, Primary, 3;Pulmonary Hypertension, Primary, 4;Cardiomyopathy Right Ventricular	Drug: Spironolactone;Drug: Placebo;Radiation: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82;Diagnostic Test: Cardiac MRI (Gadolinium enhanced)	Ottawa Heart Institute Research Corporation	NULL	Completed	18 Years	N/A	All	15	Phase 4	Canada
2	NCT02253394 (ClinicalTrials.gov)	September 2015	17/9/2014	The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study	The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)	Pulmonary Arterial Hypertension	Drug: Ambrisentan plus Spironolactone;Drug: Ambrisentan plus Placebo	Brigham and Women's Hospital	Gilead Sciences	Terminated	18 Years	N/A	All	2	Phase 4	United States
3	NCT01712620 (ClinicalTrials.gov)	January 10, 2014	20/10/2012	Spironolactone for Pulmonary Arterial Hypertension	A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Spironolactone;Drug: Placebo	National Institutes of Health Clinical Center (CC)	National Heart, Lung, and Blood Institute (NHLBI);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);University of Pennsylvania;University of Maryland Medical Center;Medstar Health Research Institute;New England Medical Center, Tufts University School of Medicine	Recruiting	18 Years	N/A	All	70	Phase 2	United States
4	NCT01468571 (ClinicalTrials.gov)	July 2011	3/11/2011	Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension	Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension	Pulmonary Hypertension	Drug: Spironolactone;Drug: Placebo	Baylor College of Medicine	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	18 Years	N/A	Both	50	Phase 4	United States
5	NCT00811486 (ClinicalTrials.gov)	January 2009	18/12/2008	Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure	Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure	Right Heart Failure;Pulmonary Hypertension	Drug: Spironolactone and conivaptan	University of Colorado, Denver	NULL	Withdrawn	18 Years	75 Years	Both	0	N/A	United States
6	NCT00240656 (ClinicalTrials.gov)	October 2005	17/10/2005	Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension	Official Title: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease—Focus on Pulmonary Artery Remodeling	Hypertension, Pulmonary	Drug: spironolactone captopril carvedilol	Hebei Medical University	NULL	Completed	N/A	80 Years	Both		Phase 1	China

先頭へ

113. 筋ジストロフィー

---

臨床試験数 : 646 /  薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03777319 (ClinicalTrials.gov)	December 5, 2018	10/12/2018	Spironolactone Versus Prednisolone in DMD	A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD	Muscular Dystrophy, Duchenne	Drug: Spironolactone;Drug: Prednisolone	Kevin Flanigan	Muscular Dystrophy Association	Terminated	4 Years	7 Years	Male	2	Phase 1	United States
2	NCT02354352 (ClinicalTrials.gov)	March 20, 2015	27/1/2015	Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy	Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: Eplerenone;Drug: Spironolactone	Ohio State University	University of California, Los Angeles;University of Utah;University of Colorado, Denver;University of Kansas Medical Center;Vanderbilt University Medical Center	Completed	7 Years	N/A	Male	52	Phase 3	United States

210. 単心室症

---

臨床試験数 : 51 /  薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04901975 (ClinicalTrials.gov)	February 11, 2021	14/5/2021	Fibrosis and the Fontan	Acute Imposition of Fontan Physiology in The Single Ventricle Patient: Effects on Fibrosis, Function and Drug Intervention	Single-ventricle	Drug: Spironolactone	Children's Hospital of Philadelphia	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	1 Year	6 Years	All	120	Phase 1/Phase 2	United States
2	NCT00211081 (ClinicalTrials.gov)	November 2004	13/9/2005	Spironolactone in Patients With Single Ventricle Heart	Impact of Spironolactone on Endothelial Function in Patients With Single Ventricle Heart	Congenital Disorders	Drug: Spironolactone (drug)	Emory University	NULL	Completed	18 Years	N/A	All	12	N/A	United States

218. アルポート症候群

---

臨床試験数 : 30 /  薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02378805 (ClinicalTrials.gov)	July 1995	26/2/2015	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies	Familial Benign Hematuria;Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease	Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol;Drug: SGLT2 inhibitor	University Hospital Goettingen	Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine	Recruiting	N/A	N/A	All	500		Germany

225. 先天性腎性尿崩症

---

臨床試験数 : 15 /  薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-003360-56-DK (EUCTR)	28/08/2009	07/07/2009	Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY	Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY	Kongenit nefrogen diabetes insipidus MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: Confortid INN or Proposed INN: INDOMETACIN Trade Name: Losec INN or Proposed INN: OMEPRAZOLE MAGNESIUM Trade Name: Viagra Other descriptive name: SILDENAFIL CITRATE Trade Name: Miacalcic Other descriptive name: CALCITONIN (SALMON) Trade Name: Spirix Other descriptive name: SPIRONOLACTONE Trade Name: Esidrix Product Name: Esidrix INN or Proposed INN: HYDROCHLOROTHIAZIDE	Dept. of Pediatrics, The Childrens Hospital, Denver	NULL	Not Recruiting			Female: no Male: yes	40		Denmark

先頭へ